Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC1-KLH + QS-21 (Memorial Sloan Kettering Cancer Center, 4da2e7)
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
MUC1-KLH + QS-21 is an investigational therapeutic cancer vaccine developed by Memorial Sloan Kettering Cancer Center (MSKCC) for the treatment of prostate cancer, specifically for patients with biochemical recurrence (rising PSA levels). The vaccine is composed of a synthetic glycopeptide derived from Mucin-1 (MUC1), a glycoprotein that is overexpressed and aberrantly glycosylated in various malignancies, including prostate cancer. To overcome the low immunogenicity of the MUC1 peptide, it is chemically conjugated to Keyhole Limpet Hemocyanin (KLH), a potent carrier protein. The vaccine is co-administered with the saponin-based adjuvant QS-21 to enhance the induction of both humoral (antibody) and cellular immune responses against tumor cells expressing the MUC1 antigen.
- Other names
- MUC1-KLH vaccine/QS21MUC-1-KLH conjugate plus QS21MUC1-KLH conjugate plus QS21MUC 1-KLH conjugate plus QS21MUC-1-KLH conjugate vaccineMUC1-KLH conjugate vaccineMUC 1-KLH conjugate vaccine
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on MUC1-KLH + QS-21 (Memorial Sloan Kettering Cancer Center, 4da2e7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUC1-KLH + QS-21 (Memorial Sloan Kettering Cancer Center, 4da2e7).